✦ LIBER ✦

Fas and Fas ligand: lpr and gld mutations

✍ Scribed by Shigekazu Nagata; Takashi Suda

Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 671 KB
Volume: 16
Category: Article
ISSN: 0167-5699
DOI: 10.1016/0167-5699(95)80069-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

gld/gld mice are unable to express a fun

gld/gld mice are unable to express a functional ligand for Fas

✍ Fred Ramsdell; Michael S. Seaman; Robert E. Miller; Teresa W. Tough; Mark R. Ald 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 600 KB

The lpr and gld genes in systemic autoim

The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane

✍ Philip L Cohen; Robert A Eisenberg 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 213 KB

Fas and Fas ligand in human hepatocellul

Fas and Fas ligand in human hepatocellular carcinoma

✍ Tetsuo Takehara; Norio Hayashi 📂 Article 📅 2001 🏛 Springer Japan 🌐 English ⚖ 38 KB

Fas and Fas ligand expression in Alzheim

Fas and Fas ligand expression in Alzheimer's disease

✍ I. Ferrer; B. Puig; J. Krupinski; M. Carmona; R. Blanco 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 344 KB

Cholangiocarcinomas express fas ligand a

Cholangiocarcinomas express fas ligand and disable the fas receptor

✍ Florencia G. Que; Vy A. Phan; Van H. Phan; Adrianne Celli; Kenneth Batts; Nichol 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB

Cholangiocarcinoma is a highly-malignant adenocarcinoma originating from cholangiocytes. Current concepts support escape from immune surveillance using aberrant expression of Fas ligand (FasL) and dysregulation of receptor (FasR) signaling as a potential mechanism for tumor progression. Our aims wer

Immunolocalization of FAS and FAS ligand

Immunolocalization of FAS and FAS ligand in inflammatory myopathies

✍ Jan L. De Bleecker; Veronique I. Meire; Iris E. Van Walleghem; Iris M. Groessens 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 179 KB